Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Infliximab biosimilar by Xentria for Pulmonary Sarcoidosis: Likelihood of Approval
Infliximab biosimilar is under clinical development by Xentria and currently in Phase II for Pulmonary Sarcoidosis. According to GlobalData, Phase...
Data Insights
Infliximab biosimilar by Celltrion for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Infliximab biosimilar is under clinical development by Celltrion and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to...